PD-1/PD-L1-IN-64

PD-1/PD-L1-IN-64 (compound 7c) potently blocks PD-1/PD-L1 interaction and restores activation of Jurkat-EC cells co-cultured with CHO/TCRAct/PD-L1 cells, with an EC₅₀ of 56 nM^[1].
PD-1/PD-L1-IN-64 potently blocks PD-1/PD-L1 interaction and restores activation of Jurkat-EC cells co-cultured with RKO/TCRAct human colon cancer cells, with an EC₅₀ of 15 nM^[1].
PD-1/PD-L1-IN-64 (0.1-2.5 μM; 48 h) activates primary human CD4⁺ and CD8⁺ T cells from healthy donors co-cultured with CHO/TCRAct/PD-L1 cells, as evidenced by increased PD-1 expression^[1].
PD-1/PD-L1-IN-64 (30 min) alters the subcellular localization of PD-L1 in U-2 OS/PD-L1/SNAPtag cells, inducing formation of PD-L1-containing granules indicative of receptor internalization^[1].
PD-1/PD-L1-IN-64 (2.5 μM; 5 days) enhances proliferation and activation of human PBLs co-cultured with RKO/TCRAct cells, leading to increased elimination of cancer cells without reducing T cell viability^[1].
PD-1/PD-L1-IN-64 promotes oligomerization of recombinant human PD-L1, but not recombinant murine PD-L1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.